Finally, hyperactivation of the PI3K pathway is linked to resistance to endocrine therapy in ER+ breast cancer cell lines [48] and to anti‐HER2 therapy in transgenic mice [49]. The gene discussed is ERBB2; the disease is breast carcinoma.